Frontlight ResearchEarly access
WithdrawnNo phase
A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
Key facts
- Who runs it
- Addario Lung Cancer Medical Institute
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Sept 2025
- Expected to end
- Dec 2026
- Type of study
- Observational
- Record updated
- 4 August 2026
- Why it stopped
- Sponsor/Funder decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult men or women meeting Age of Majority (AOM) at the time of consent
- Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF)
- Any diagnosis of SCLC
- Willing to provide clinical and medical information related to his/her cancer diagnoses to the study team as required
- Willing to comply with the requirements of the study
Who cannot take part
- Has been diagnosed with non-tumor Lamber-Eaton Myasthenic syndrome (LEMS) > 1 year prior to the SCLC diagnosis
- Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements
Where in United States
- Dana-Farber Cancer InstituteBoston, United States
About the trial
What the trial wants to find out
This is a multi-center observational study in subjects with a diagnosis of small cell lung cancer. Screening and/or medical record review for symptoms associated with Lambert Eaton Myasthenic Syndrome (LEMS) will be conducted.
The group in the trial
- SCLC
Diagnosis of SCLC within 1 year of enrollment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Observational Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
- Record updated
- 4 August 2026